Short Interest in Sunshine Biopharma, Inc. (NASDAQ:SBFM) Increases By 78.1%

Sunshine Biopharma, Inc. (NASDAQ:SBFM) was the target of a large increase in short interest in March. As of March 15th, there was short interest totalling 113,100 shares, an increase of 78.1% from the February 28th total of 63,500 shares. Approximately 4.2% of the shares of the stock are short sold. Based on an average daily trading volume, of 78,400 shares, the short-interest ratio is presently 1.4 days.

Analyst Upgrades and Downgrades

Separately, Aegis reaffirmed a “buy” rating and issued a $15.00 price target on shares of Sunshine Biopharma in a research note on Thursday, December 5th.

Sunshine Biopharma Stock Performance

Shares of NASDAQ:SBFM traded down $0.10 on Friday, hitting $2.00. The stock had a trading volume of 22,287 shares, compared to its average volume of 280,942. The firm’s 50 day moving average price is $2.43 and its 200-day moving average price is $2.73. Sunshine Biopharma has a twelve month low of $1.90 and a twelve month high of $265.00. The company has a market capitalization of $2.45 million, a price-to-earnings ratio of -0.01 and a beta of 1.35.

Hedge Funds Weigh In On Sunshine Biopharma

An institutional investor recently bought a new position in Sunshine Biopharma stock. Connective Capital Management LLC acquired a new position in shares of Sunshine Biopharma, Inc. (NASDAQ:SBFM) in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm acquired 11,345 shares of the company’s stock, valued at approximately $34,000. Connective Capital Management LLC owned approximately 0.93% of Sunshine Biopharma at the end of the most recent quarter. Institutional investors and hedge funds own 41.98% of the company’s stock.

Sunshine Biopharma Company Profile

Sunshine Biopharma, Inc, a pharmaceutical company, focuses on the research and development of life-saving medicines in various therapeutic areas, including oncology and antivirals in the United States and Canada. It operates in two segments, Prescription Generic Pharmaceuticals and Nonprescription Over-The-Counter Products.